

**I PER-CORSI  
IN  
NEFROLOGIA  
E DIALISI**

**II CORSO  
L'ACCESSO DIALITICO**

**14 ottobre 2022  
NH Hotel Pontevecchio  
Lecco**

**Scelta dell'accesso vascolare per emodialisi**  
**Mapping ecografico/flebografico  
dei vasi degli arti superiori**

Dott.ssa Sara Colzani

Sistema Socio Sanitario



## Associations between Hemodialysis Access Type and Clinical Outcomes: A Systematic Review




Pietro Ravani,<sup>\*†‡</sup> Suetonia C. Palmer,<sup>§</sup> Matthew J. Oliver,<sup>||</sup> Robert R. Quinn,<sup>\*†‡</sup>  
Jennifer M. MacRae,<sup>\*</sup> Davina J. Tai,<sup>\*||</sup> Neesh I. Pannu,<sup>\*\*</sup> Chandra Thomas,<sup>\*</sup>  
Brenda R. Hemmelgarn,<sup>\*†‡</sup> Jonathan C. Craig,<sup>††‡‡§§</sup> Braden Manns,<sup>\*†‡</sup> Marcello Tonelli,<sup>\*\*</sup>  
Giovanni F.M. Strippoli,<sup>‡‡§§||††</sup> and Matthew T. James<sup>\*†‡</sup>

Departments of <sup>\*</sup>Medicine and <sup>†</sup>Community Health Sciences and <sup>‡</sup>Libin Cardiovascular Institute of Alberta, University of Calgary, Calgary, Alberta, Canada; <sup>§</sup>Department of Medicine, University of Otago Christchurch, Christchurch, New Zealand; <sup>||</sup>Department of Medicine, University of Toronto, Toronto, Ontario, Canada; <sup>¶</sup>Department of Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada; <sup>\*\*</sup>Department of Medicine, University of Alberta, Edmonton, Alberta, Canada; <sup>††</sup>Clinical Research Centre for Kidney Research, The Children's Hospital at Westmead, Westmead, Australia; <sup>‡‡</sup>National Health and Medical Research Council Centre for Clinical Research Excellence in Renal Medicine, Cochrane Renal Group, Sydney, Australia; <sup>§§</sup>School of Public Health, University of Sydney, Sydney, Australia; <sup>|||</sup>Laboratory of Clinical Epidemiology of Diabetes and Chronic Diseases, Mario Negri Sud Consortium, S. Maria Imbaro (Chieti), Italy; and <sup>†††</sup>Diaverum Medical Scientific Office, Lund, Sweden

Ravani, P., Palmer, S. C., Oliver, M. J., Quinn, R. R., MacRae, J. M., Tai, D. J., Pannu, N. I., Thomas, C., Hemmelgarn, B. R., Craig, J. C., Manns, B., Tonelli, M., Strippoli, G. F., & James, M. T. (2013). Associations between hemodialysis access type and clinical outcomes: a systematic review. *Journal of the American Society of Nephrology : JASN*, 24(3), 465–473.


# Scelta dell'accesso vascolare per emodialisi

meta-analisi (62 studi di coorte)  
risk of all-cause mortality



Ravani, P., Palmer, S. C., Oliver, M. J., Quinn, R. R., MacRae, J. M., Tai, D. J., Pannu, N. I., Thomas, C., Hemmelgarn, B. R., Craig, J. C., Manns, B., Tonelli, M., Strippoli, G. F., & James, M. T. (2013). Associations between hemodialysis access type and clinical outcomes: a systematic review. *Journal of the American Society of Nephrology : JASN*, 24(3), 465–473.


# Scelta dell'accesso vascolare per emodialisi



meta-analisi (62 studi di coorte)  
 risk of all-cause mortality  
 infezioni fatale e non fatale  
 eventi cardiovascolari maggiori\*  
 ospedalizzazione

Ravani, P., Palmer, S. C., Oliver, M. J., Quinn, R. R., MacRae, J. M., Tai, D. J., Pannu, N. I., Thomas, C., Hemmelgarn, B. R., Craig, J. C., Manns, B., Tonelli, M., Strippoli, G. F., & James, M. T. (2013). Associations between hemodialysis access type and clinical outcomes: a systematic review. *Journal of the American Society of Nephrology : JASN*, 24(3), 465–473.

# Scelta dell'accesso vascolare per emodialisi



elderly  
nonelderly

28% lower-arm  
20% upper-arm  
37% elderly  
27% nonelderly

nonelderly  
elderly

lower-arm  
upper-arm

upper-arm  
lower-arm

placebo  
clopidogrel

mapping ecografico



## Fallimento primario della FAV nativa

- Meta-analisi di studi osservazionali
- dati raccolti prospetticamente
- follow up di almeno 3 mesi
- studi con 100 o più fistole
- dati pubblicati tra gennaio del 2000 e giugno del 2012

definizione: trombosi entro 72 ore, non utilizzabile entro 3 mesi (early) o 6 (late)



# Scelta dell'accesso vascolare per emodialisi



**Table 2.**

Frequency of interventions before successful AVF use (assisted maturation) in published studies


Reference	Patient Source	Percent of Patients with Assisted AVF Maturation
Falk (48)	Access ambulatory center	58%
Lee <i>et al.</i> (18)	Two academic centers	44%
Harms <i>et al.</i> (16)	One academic center	50%
Allon <i>et al.</i> (8)	Seven academic centers (HFM Study)	27%
Lee <i>et al.</i> (17)	US Renal Data System	42%

AVF, arteriovenous fistula; HFM, Hemodialysis Fistula Maturation.

Allon M. Vascular Access for Hemodialysis Patients: New Data Should Guide Decision Making. *Clin J Am Soc Nephrol.* 2019 Jun 7;14(6):954-961

Lok CE, Sontrop JM, Tomlinson G, Rajan D, Cattral M, Oreopoulos G, Harris J, Moist L. Cumulative patency of contemporary fistulas versus grafts (2000-2010). *Clin J Am Soc Nephrol.* 2013 May;8(5)

# Scelta dell'accesso vascolare per emodialisi



Allon M. Vascular Access for Hemodialysis Patients: New Data Should Guide Decision Making. Clin J Am Soc Nephrol. 2019 Jun 7;14(6):954-961

Brown RS, Patibandla BK, Goldfarb-Rumyantzev AS. The Survival Benefit of "Fistula First, Catheter Last" in Hemodialysis Is Primarily Due to Patient Factors. J Am Soc Nephrol. 2017 Feb;28(2):645-652

## Scelta dell'accesso vascolare per emodialisi

The KDOQI 2006 Vascular Access Update  
and **Fistula First** Program Synopsis

**KDOQI**<sup>®</sup>

KIDNEY DISEASE OUTCOMES  
QUALITY INITIATIVE

National Kidney Foundation

**KDOQI CLINICAL PRACTICE GUIDELINE FOR VASCULAR  
ACCESS: 2019 UPDATE**

life-plan  
patient first



# Scelta dell'accesso vascolare per emodialisi

## 1.anamnesi

età

razza

sexso

diabete mellito

tempo di dialisi

ipertensione arteriosa

cardiopatìa

vasculopatìa periferica

PM

precedenti CVC

precedenti accessi vascolari

neoplasia

disordini della coagulazione

fragilità

obesità

arto dominante

# Scelta dell'accesso vascolare per emodialisi

## 1.anamnesi

## Fattori demografici età

**Table 2** VA advantages and disadvantages in the elderly

	Advantages	Disadvantages
Pre-emptive AVF	No age limit for this procedure with adequate vessels Lower infection rates compared to CVC and AVG Better survival (?) Patients can shower	Competing risk of death before HD start Higher rates of failure to mature compared to AVG More AVFs created than used (increased morbidity and costs)
AVF after dialysis start	Surgery as needed Most functioning AVF will be used Advantages of pre-emptive AVF are maintained, but CVC is needed	Start of dialysis with a CVC Higher AVF dysfunction and infection rates compared to pre-emptive AVF Higher rates of failure to mature compared to AVG With low mean survival, actual AVF utilization may be short
AVG	Short timing from procedure to use (days–weeks) Lower infection rates compared to CVC	Higher cost Needs accurate maintenance with interventional procedures
CVC	Quick and easy procedure No needle punctures Higher patient preference	Increased infection rates, carrying higher morbidity and mortality

Lomonte C, Forneris G, Gallieni M, Tazza L, Meola M, Lodi M, Senatore M, Morale W, Spina M, Napoli M, Bonucchi D, Galli F. The vascular access in the elderly: a position statement of the Vascular Access Working Group of the Italian Society of Nephrology. *J Nephrol.* 2016 Apr;29(2):175-184. doi: 10.1007/s40620-016-0263-z. Epub 2016 Jan 16. Erratum in: *J Nephrol.* 2017 Aug;30(4):617. PMID: 26780568; PMCID: PMC5429362.

# Scelta dell'accesso vascolare per emodialisi

## 1.anamnesi

età

razza

Sesso

diabete mellito

tempo di dialisi

ipertensione arteriosa

cardiopatìa

vasculopatìa periferica

PM

precedenti CVC

precedenti accessi vascolari

neoplasia

disordini della coagulazione

fragilità

obesità

arto dominante

	Entire study population (n = 20,360)		"Early" AVF placement group (n = 11,258)	
	Odds ratio (95% CI)	P value	Odds ratio (95% CI)	P value
Age at onset of ESRD	1.01 (1.00–1.01)	0.006	1.01 (1.00–1.02)	0.003
Female (vs male)	1.55 (1.46–1.65)	<0.001	1.69 (1.55–1.83)	<0.001
White	Reference		Reference	
Black	1.33 (1.22–1.45)	<0.001	1.41 (1.26–1.58)	<0.001
Asian	0.91 (0.77–1.08)	0.27	0.90 (0.71–1.13)	0.36
Native American	1.13 (0.80–1.60)	0.50	1.23 (0.78–1.94)	0.37
Other	2.45 (0.50–11.98)	0.27	0.82 (0.05–4.73)	0.89
Time between access placement and hemodialysis initiation (in months)	0.94 (0.94–0.95)	<0.001	1.00 (0.99–1.01)	0.72
Body mass index (kg/m <sup>2</sup> )	1.01 (1.00–1.01)	0.013	1.00 (1.00–1.01)	0.33
Primary cause of ESRD				
Diabetes	Reference		Reference	
Hypertension	1.00 (0.90–1.11)	0.56	1.00 (0.85–1.11)	0.72
Glomerulonephritis	0.83 (0.71–0.97)	0.007	0.75 (0.60–0.93)	0.005
Cystic disease	0.92 (0.73–1.15)	0.51	0.97 (0.73–1.29)	0.91
Other	1.32 (0.99–1.75)	0.013	1.27 (0.88–1.84)	0.06
Presence of diabetes	1.20 (1.09–1.33)	0.0003	1.22 (1.06–1.39)	0.005
Presence of peripheral vascular disease	1.06 (0.98–1.14)	0.18	1.06 (0.95–1.18)	0.29
Presence of malignancy	1.06 (0.96–1.17)	0.28	1.03 (0.90–1.18)	0.64
Presence of cerebrovascular disease	1.13 (1.03–1.24)	0.01	1.22 (1.07–1.38)	0.002
Presence of congestive heart failure	1.30 (1.22–1.39)	<0.001	1.26 (1.15–1.37)	<0.001
Duration of pre-ESRD nephrology care (mo)				
>12	Reference		Reference	
6–12	1.24 (1.15–1.33)	<0.001	1.3 (1.18–1.43)	<0.001
<6	1.27 (1.16–1.39)	<0.001	1.22 (1.07–1.38)	<0.001
Zero	4.17 (3.58–4.86)	<0.001	4.09 (3.35–5.00)	<0.001
Missing data	3.04 (2.64–3.50)	0.002	3.28 (2.73–3.94)	0.09
Income (annual per family)	1.00 (1.00–1.00)	0.52	1.00 (1.00–1.00)	0.37
Employment status				
Unemployed	Reference		Reference	
Retired	1.00 (0.90–1.10)	0.04	1.00 (0.85–1.12)	0.20
Working part time	0.86 (0.66–1.12)	0.55	0.80 (0.55–1.17)	0.39
Working full time	0.81 (0.65–1.00)	0.14	0.85 (0.63–1.15)	0.60
History of smoking (no vs. yes)	1.02 (0.87–1.20)	0.81	1.00 (0.80–1.25)	0.97
Alcohol dependence (no vs. yes)	1.47 (0.90–2.41)	0.12	1.13 (0.62–2.05)	0.69
Drug dependence (no vs. yes)	2.18 (0.62–7.69)	0.22	2.22 (0.45–10.90)	0.32
Geographic location				
Rural	Reference		Reference	
Urban	1.02 (0.95–1.10)	0.39	1.09 (1.00–1.21)	0.68
Unknown	0.91 (0.68–1.22)	0.48	1.10 (0.76–1.59)	0.79

## 1.anamnesi

fattori di rischio

analisi retrospettiva  
20360 pz ≥ 65 aa USRDS

# Scelta dell'accesso vascolare per emodialisi

REGULAR ARTICLE | VOLUME 74, ISSUE 1, P8-10, JANUARY 01, 1998

## Incidence and Characteristics of Patients with Hand Ischemia after a Hemodialysis Access Procedure

Amro H. Morsy, M.D. • Mark Kulbaski, M.D. • Changyi Chen, M.D., Ph.D. • Halit Isiklar, M.D. •

Alan B. Lumsden, M.D.

Studio retrospettivo su 352 pz sottoposti a 409 interventi tra febbraio '92 e gennaio '97 c/o Emory University Hospital



15 hanno sviluppato una **steal syndrome**

Clinical characteristics of patients with hand ischemia included long-standing insulin-dependent diabetes (10), chronic hypertension (12), peripheral arterial disease (14; 93.3%), coronary artery disease (8), and systemic lupus erythematosus (1). Severe peripheral arterial diseases are commonly found and may be markers for risk of hand ischemia after access surgery.

# Scelta dell'accesso vascolare per emodialisi

Variable	Subgroup		
	Participants without ARHI (n = 576)	Participants with ARHI (cases) (n = 26)	Weighted, <sup>a</sup> matched controls (n = 235)
	% or mean ± SD		
Age at time of consent, years	54.9 ± 13.5	59.6 ± 9.9	59.1 ± 9.5
Female	28.8	53.8	53.8
Diabetes	57.1	92.3	92.3
AVF in upper arm	75.5	92.3	92.3
Peripheral artery disease	15.5	30.8	22.0
Coronary artery disease	24.8	50.0	29.9
Hypertension	96.5	96.2	99.4
Prior permanent hemodialysis access in the index AVF arm	22.2	11.5	22.6
Functional hemodialysis catheter ipsilateral to AVF	33.6	38.9	22.2
Current hemodialysis or peritoneal dialysis	64.1	69.2	56.9
Smoking status			
Never	45.9	38.5	52.1
Former	37.0	34.6	34.3
Current	17.2	26.9	13.5
Length of anastomosis, mm	7.8 ± 2.8	8.8 ± 2.1	7.7 ± 1.2
Preoperative feeding artery diameter, mm	0.38 ± 0.12	0.40 ± 0.08	0.40 ± 0.07
Preoperative radial artery diameter at wrist, mm	0.22 ± .053	0.21 ± 0.05	0.20 ± 0.30
Mean preoperative draining vein diameter, mm	0.37 ± 0.12	0.40 ± 0.11	0.38 ± 0.04
Minimum preoperative draining vein diameter, mm	0.30 ± 0.11	0.32 ± 0.11	0.30 ± 0.04
AVF configurations			
Upper arm cephalic vein and antecubital/proximal forearm artery	46.9	57.7	52.6
Upper arm basilic vein transposition and antecubital artery/proximal forearm artery	26.7	30.8	35.9
Upper arm brachial vein transposition and antecubital artery	1.9	3.9	3.8

Studio americano multicentrico, prospettico, osservazionale  
602 partecipanti, follow up di 4 anni

No interventi per favorire la maturazione  
nelle prime 6 settimane  
ARHI outcome secondario  
45 pazienti

**steal syndrome**

Variable	Subgroup		
	Participants without ARHI (n = 576)	Participants with ARHI (cases) (n = 26)	Weighted, <sup>a</sup> matched controls (n = 235)
	% or mean ± SD		
Forearm cephalic vein and wrist radial artery	22.7	7.7	7.7
Forearm basilic vein transposition and wrist radial artery	1.7	0	0
AVF classification based on feeding artery			
Brachial artery	62.7	84.6	78.3
Distal radial artery	24.5	7.7	7.7
Antecubital artery	10.6	7.7	8.1
Proximal radial artery	2.3	0	5.9



# Scelta dell'accesso vascolare per emodialisi

## steal syndrome

<i>Risk factor</i>	<i>No.<sup>b</sup></i>	<i>OR (95% CI)</i>	<i>P value<sup>e</sup></i>
Age (per decade) <sup>d</sup>	470	1.16 (0.72-1.86)	.55
<u>Female vs male<sup>c</sup></u>	319	3.17 (1.27-7.91)	<b>.013</b>
<u>Diabetes<sup>f</sup></u>	389	13.62 (1.81-102.4)	<b>.011</b>
Peripheral artery disease	261	1.91 (0.75-4.88)	.17
<u>Coronary artery disease</u>	261	2.60 (1.03-6.58)	<b>.044</b>
Hypertension	261	0.35 (0.03-4.55)	.42
Smoking (never; former; current; per more current category)	259	1.56 (0.90-2.69)	.11
Prior permanent hemodialysis access in the index AVF arm	115	0.33 (0.071-1.53)	.16
Functional hemodialysis catheter ipsilateral to AVF	113	0.79 (0.32-1.94)	.60
Current hemodialysis or peritoneal dialysis	261	1.65 (0.63-4.27)	.31

<i>Risk factor</i>	<i>No.<sup>b</sup></i>	<i>OR (95% CI)</i>	<i>P value<sup>e</sup></i>
<b>AVF configuration</b>			
Forearm vs upper arm <sup>d</sup>	353	0.38 (0.085-1.71)	.21
High radial artery takeoff	261	1.41 (0.31-6.38)	.66
Cephalic vs transpositions (both basilic and brachial vein)	251	1.26 (0.48-3.32)	.64
Brachial transpositions vs basilic transpositions	38	0.32 (0.02-5.84)	.44
<b>Surgical technique</b>			
Length of anastomosis (per 1 mm)	107	1.12 (0.88-1.42)	.34
<b>Vascular characteristics</b>			
Preoperative feeding artery diameter (per 1 mm)	243	1.26 (0.006-260)	.93
Preoperative radial artery diameter (per 1 mm)	245	1.45 (0.60-3.49)	.41
Mean preoperative draining vein diameter (per 1 mm)	234	1.09 (0.76-1.57)	.64
Minimum preoperative draining vein diameter (per 1 mm)	234	1.14 (0.78-1.65)	.51
Preoperative upper arm fistula feeding artery flow (per 10 mL/min)	226	0.99 (0.93-1.07)	.87
Preoperative feeding artery ultrasound calcification (none or mild vs moderate or severe)	260	0.91 (0.45-1.87)	.80
Draining vein histologic calcification (intimal or medial vs none)	222	2.46 (0.73-8.28)	.14
<b>Brachial artery dilation measures</b>			
Brachial artery FMD% (per %)	211	0.93 (0.83-1.04)	.22
Brachial artery NMD% (per %)	125	0.98 (0.89-1.08)	.72
<b>Arterial stiffness measures</b>			
Carotid-femoral PWV (per m/s)	124	1.14 (0.99-1.32)	.080
Carotid-radial PWV (per m/s)	124	1.02 (0.73-1.44)	.90
<b>Vein function measures</b>			
<u>Capacitance slope (per %/10 mm Hg)</u>	234	2.76 (1.07-6.52)	<b>.021</b>
<u>Maximum venous outflow slope (per [mL/100 mL/min]/10 mm Hg)</u>	234	1.13 (1.03-1.25)	<b>.011</b>

## Scelta dell'accesso vascolare per emodialisi




di fronte a paziente a rischio:  
a cosa prestare attenzione per prevenire **steal syndrome**?

- tipo di accesso vascolare
- sede dell'accesso vascolare
- lunghezza dell'anastomosi
- stenosi critiche da trattare prima dell'allestimento

# Scelta dell'accesso vascolare per emodialisi

## Scompenso ad alta portata

Perché non tutti i pazienti?



Most patients tolerate the increased cardiac output and increased oxygen demand caused by fistula creation through various cardiac adaptations that increase filling pressures and cardiac performance. However, patients with underlying ischemic or valvular heart disease may not be able to sustain the cardiac remodeling requirements, making them more susceptible to developing heart failure.

# Scelta dell'accesso vascolare per emodialisi

Scompenso ad alta portata

562 paziente con IRC avanzata (stadio IV-V) seguiti dal 2004 al 2010 studio prospettico osservazionale

	All patients	Patients with CHF	Patients without CHF
No. patients	562	95	467
Age (years)	65±15	72±8 <sup>c</sup>	64±15
Sex (male/female)	302/260	39/56 <sup>a</sup>	263/204
Diabetic (%)	31	45 <sup>a</sup>	29
Comorbidity index, absent/mild-moderate/severe	191/268/103	11/57/27 <sup>c</sup>	180/211/76
Ischaemic heart disease (%)	17	32 <sup>c</sup>	14
Cerebral ischaemia (%)	13	15	13
Peripheral ischaemia (%)	9	9	9
History of CHF (%)	15	36 <sup>c</sup>	11
Atrial fibrillation (%)	10	25 <sup>c</sup>	7
Body mass index (kg/m <sup>2</sup> )	29.6±5.9	31.6±6.7 <sup>c</sup>	29.2±5.7
Systolic blood pressure (mm Hg)	153±26	162±28 <sup>c</sup>	152±25
Diastolic blood pressure (mm Hg)	86±14	85±12	86±14
Glomerular filtration rate (ml/min/1.73m <sup>2</sup> )	15.1±5.0	15.9±4.9	14.9±5.0
Proteinuria (mg/g) creatinine	2376±2902	2985±2866 <sup>a</sup>	2252±2896
Haemoglobin (g/dl)	11.7±1.7	11.6±1.7	11.7±1.8
Serum uric acid (mg/dl)	7.5±1.8	7.65±2.1	7.5±1.8
Serum albumin (g/dl)	3.86±0.47	3.75±0.42	3.88±0.48
Total cholesterol (mg/dl)	191±49	195±46	189±49
Triglycerides (mg/dl)	145±105	164±151	141±92
Total serum calcium (mg/dl)	9.24±0.81	9.19±0.75	9.24±0.82
Serum phosphorous (mg/dl)	4.59±1.06	4.54±1.15	4.60±1.04
Alkaline phosphatase (IU/l)	98±48	110±65 <sup>a</sup>	95±44
Bicarbonate (mmol/l)	21.7±3.6	22.6±3.9 <sup>a</sup>	21.6±3.6
Parathyroid hormone (pg/ml)	239±196	246±177	238±199
Diuretics (%)	58	80 <sup>c</sup>	53
ACE inhibitor/ARB (%)	74	74	74
Beta blockers (%)	24	42 <sup>c</sup>	20
Erythropoietin (%)	67	73	66
Functioning AVF (%)	28	50 <sup>c</sup>	24
Distal AVF (%)	9	5	10
Proximal AVF (%)	19	45 <sup>c</sup>	14

Martínez-Gallardo R, Ferreira-Morong F, García-Pino G, Cerezo-Arias I, Hernández-Gallego R, Caravaca F. Congestive heart failure in patients with advanced chronic kidney disease: association with pre-emptive vascular access placement. *Nefrologia*. 2012;32(2):206-12

# Scelta dell'accesso vascolare per emodialisi

Scompenso ad alta portata

**Table 2.** Influential factors in the development of decompensated heart failure in our patients, as determined by multiple logistic regression


Variable	OR	95% CI OR	P
Age, years	1.052	1.022; 1.082	<0.0001
Sex (male 1, female 0)	0.523	0.308; 0.888	0.016
Systolic blood pressure (mm Hg)	1.013	1.002; 1.023	0.017
Baseline GFR (ml/min/1.73m <sup>2</sup> )	1.101	1.039; 1.167	0.001
History of ischaemic heart disease (0.1)	2.488	1.276; 4.852	0.007
History of CHF (0.1)	2.517	1.283; 4.939	0.007
History of atrial fibrillation (0.1)	2.820	1.304; 6.101	0.008
Beta blockers (0.1)	1.805	1.010; 3.224	0.046
Functioning AVF (0.1)	9.541	4.841; 18.806	<0.0001

562 paziente con IRC avanzata (stadio IV-V) seguiti dal 2004 al 2010  
studio prospettico osservazionale  
160 allestimento FAV  
endpoint un episodio di scompenso

Martínez-Gallardo R, Ferreira-Morong F, García-Pino G, Cerezo-Arias I, Hernández-Gallego R, Caravaca F. Congestive heart failure in patients with advanced chronic kidney disease: association with pre-emptive vascular access placement. *Nefrologia*. 2012;32(2):206-12

# Scelta dell'accesso vascolare per emodialisi

Scompenso ad alta portata



86 pazienti

determinazione di Qa e CO mediante Transonic

ricircolo cardiopolmonare  $CPR = Qa/CO$

carico di lavoro del ventricolo sinistro  $LLV = TPVR * CO_2$



# Scelta dell'accesso vascolare per emodialisi

Scompenso ad alta portata


**Table 1.** Demographic, clinical and haemodynamic data for the 86 patients enrolled into the study (data are reported for both the entire cohort and for their categorization into lower and upper arm AVFs)

	All (n = 86)	Lower arm (n = 56)	Upper arm (n = 30)	P
Age (years)	61.0 (11.0)	58.6 (9.4)	63.4 (11.9)	0.453 <sup>a</sup>
Gender (males) (%)	53.8	57.2	50.4	0.142 <sup>b</sup>
Diabetes mellitus (%)	15.6	15.5	15.7	0.876 <sup>b</sup>
Dialysis duration (months)	59.6 (22.9)	65.0 (18.4)	54.2 (21.9)	<0.0001 <sup>c</sup>
Haemoglobin (g/dL)	11.6 (1.3)	11.2 (1.7)	12.0 (2.1)	0.654 <sup>a</sup>
AVF vintage (months)	74.4 (65.4)	79.8 (62.6)	69.0 (65.7)	<0.0001 <sup>c</sup>
MAP (mmHg)	92.7 (13.9)	92.0 (15.1)	93.4 (12.4)	0.320 <sup>c</sup>
Heart rate (beats/min)	72.7 (9.5)	71.2 (11.5)	74.2 (8.4)	0.540 <sup>c</sup>
CO (L/min)	6.3 (1.3)	5.7 (1.0)	6.8 (1.0)	<0.0001 <sup>a</sup>
Qa (L/min)	1.3 (0.6)	0.9 (0.3)	1.6 (0.4)	<0.0001 <sup>c</sup>
LLV (watt)	1.3 (0.6)	1.0 (0.3)	1.6 (0.4)	<0.0001 <sup>a</sup>
CPR	0.2 (0.3)	0.1 (0.1)	0.3 (0.1)	<0.0001 <sup>c</sup>
LLV <sub>AVF</sub> (% of LLV)	19.7 (3.1)	15.8 (3.2)	23.5 (4.0)	<0.0001 <sup>a</sup>
TPVR (mmHg·min/L)	14.9 (3.2)	16.1 (4.2)	13.7 (3.2)	<0.0001 <sup>a</sup>
AR (mmHg·min/L)	80.3 (24.6)	102.2 (21.8)	58.3 (15.9)	<0.0001 <sup>c</sup>
SVR (mmHg·min/L)	18.6 (4.1)	19.2 (5.3)	17.9 (5.1)	<0.0001 <sup>c</sup>

# Scelta dell'accesso vascolare per emodialisi

Scompenso ad alta portata

relazione tra portata e scompenso?



# Scelta dell'accesso vascolare per emodialisi

## Scompenso ad alta portata

perché alta portata?

- fattori demografici: età giovane, sesso maschile
- fattori legati all'intervento: sede della FAV, precedenti accessi, lunghezza dell'anastomosi
- altri fattori anatomo-fisiologici (?)

Finally, we must always bear in mind that the wrong access choice in the HF patients can endanger their life. For this reason, it would be better to apply validated predictive models to estimate the flow rate that will have the fistula after its creation or, directly, its cardiac effects.<sup>30</sup>

## Scelta dell'accesso vascolare per emodialisi



di fronte a paziente a rischio:  
a cosa prestare attenzione per ridurre possibilità di **scompenso ad alta portata**?

When planning the best vascular access for each incident HF patient, the risk of HF worsening after AV access creation must be evaluated carefully together with the risk of catheter-related complications, but avoiding a non-selective 'catheter first' approach for all HF patients.

Clinical presentation	Type of vascular access proposed
Life-threatening heart failure	Catheter
Left ventricular ejection fraction <30%	Catheter
NYHA class IV and ACC/AHA stage D	Catheter
Most NYHA class III and ACC/AHA stage C	Catheter
ACC/AHA stage A, B and certain C	Distal arm AVF
NYHA class I, II and certain III	Distal arm AVF

NYHA: New York Heart Association heart failure classification; ACC/AHA: American College of Cardiology/American Heart Association heart failure classification; AVF: arteriovenous fistula.

- tipo di accesso vascolare
- sede dell'accesso vascolare
- lunghezza dell'anastomosi
- ottimizzazione della terapia cardiologica

After 2–3 months of progressive ultrafiltration during the HD sessions through a catheter, the cardiac function must be re-evaluated by means of a new echocardiography exam to identify those HF patients showing an improvement in cardiac performance, who will benefit from an AV access creation and catheter removal.

# Scelta dell'accesso vascolare per emodialisi

## 1.anamnesi

età

razza

sexso

diabete mellito

tempo di dialisi

ipertensione arteriosa

cardiopatìa

vasculopatìa periferica

PM

precedenti CVC

precedenti accessi vascolari

neoplasia

disordini della coagulazione

fragilità

obesità

arto dominante

## Scelta dell'accesso vascolare per emodialisi

> [Semin Dial.](#) 2013 Nov-Dec;26(6):728-32. doi: 10.1111/sdi.12073. Epub 2013 Mar 5.

### **The impact of transvenous cardiac devices on vascular access patency in hemodialysis patients**

Chieh Suai Tan <sup>1</sup>, Cui Jie, Jennifer Joe, Zubin D Irani, Suvranu Ganguli, Sanjeeva Prasad Kalva, Stephan Wicky, Steven Wu

Comparing patients with arteriovenous (AV) access created ipsilateral to CIED placement (n=19) versus the contralateral side (n=17), the primary failure rate was 78.9% versus 35.3% (p=0.02).

studio retrospettivo



## Scelta dell'accesso vascolare per emodialisi

> Ann Vasc Surg. 2003 Sep;17(5):526-9. doi: 10.1007/s10016-003-0048-4. Epub 2003 Sep 10.

### Symptomatic subclavian vein stenosis and occlusion in hemodialysis patients with transvenous pacemakers

Theodore H Teruya<sup>1</sup>, Ahmed M Abou-Zamzam Jr, Whitney Limm, Linda Wong, Livingston Wong

During the 10-year period 495 patients had transvenous pacemakers placed. Twenty patients were identified with renal failure requiring hemodialysis and 14 had hemodialysis access in the extremity ipsilateral to the pacemaker. Ten (10/14, 71%) patients developed symptoms of subclavian stenosis, including venous hypertension, high recirculation rate, arm swelling, pain, and neurologic symptoms. Eighty percent (8/10) of symptomatic patients had subclavian vein occlusion. All 10 symptomatic patients required ligation of the hemodialysis access to control symptoms.

## Scelta dell'accesso vascolare per emodialisi

Patency rates	Ipsilateral (n = 13)	Contralateral (n = 15)	P value
Primary	20.2 months	22.2 months	
Primary assisted	21.2	38.0	
Secondary	39	48.8	
Six-month patency rate	69.2%	86.6%	0.375
One-year patency rate	53.8%	60%	0.62

analisi retrospettiva dal 2008 al 2016  
44 pz in follow up 28

## Scelta dell'accesso vascolare per emodialisi

After short-term catheter placement, focal areas of endothelial injury were seen in the vein wall adjacent to the catheter. Associated thrombus may or may not be present. Long-term catheters displayed vein wall thickening and bridges from the vein wall to the catheter.

Forauer AR, Theoharis C. Histologic changes in the human vein wall adjacent to indwelling central venous catheters. *J Vasc Interv Radiol.* 2003 Sep;14(9 Pt 1):1163-8

**Table 2. Primary outcomes**

AVF function, months, <i>n</i> (%)	No Tunneled Vascular Catheter	Tunneled Vascular Catheter	Odds Ratio	95% Confidence Interval	<i>P</i> Value <sup>a</sup>
6	48 out of 70 (68.6)	70 out of 129 (54.3)	1.84	1.00 to 3.39	0.05
12	70 out of 83 (84.3)	73 out of 115 (63.5)	3.10	1.53 to 6.26	0.002
	Contralateral TVC	Ipsilateral TVC	Odds Ratio	95% Confidence Interval	<i>P</i> Value <sup>b</sup>
6	56 out of 94 (59.6)	14 out of 35 (40.0)	2.21	1.01 to 4.88	0.05
12	54 out of 82 (65.9)	19 out of 33 (57.6)	1.42	0.62 to 3.25	0.40

AVF, arteriovenous fistula; TVC, tunneled vascular catheter.

<sup>a</sup>Backward conditional logistical regression applied to adjust for baseline variables (age, sex, diabetes, hypertension, and hypercholesterolemia).

<sup>b</sup>Backward conditional logistical regression applied to adjust for baseline variables, days from TVC insertion to AVF creation, and left-sided TVC.

> necessità di procedure

studio retrospettivo  
osservazionale  
287 HD pz -> 142 CVC:  
102 controlaterale  
40 omolaterale

critério clinico

Diep J, Makris A, De Guzman I, Wong J, Aravindan A, Nandakoban H, Narayanan G. Impact of Previous Tunneled Vascular Catheters and their Location on Upper Limb Arteriovenous Fistula Function. *Kidney360.* 2021 Oct 7;2(12):1953-1959

# Scelta dell'accesso vascolare per emodialisi

## 1.anamnesi

età

razza

sexso

diabete mellito

tempo di dialisi

ipertensione arteriosa

cardiopatìa

vasculopatìa periferica

PM

precedenti CVC

precedenti accessi vascolari

neoplasia

disordini della coagulazione

fragilità

obesità

arto dominante

# Scelta dell'accesso vascolare per emodialisi

## 2.esame obiettivo

### Statements: Patient Clinical Examination

7.1 KDOQI recommends that a physical examination focused on vascular anatomy be the basis for the initial assessment and planning of vascular access creation. (Conditional Recommendation, Very Low Quality of Evidence)

7.2 KDOQI considers it reasonable to have greater emphasis on and more training in preoperative clinical examination to assess patients and their vessels to determine the type and location of their vascular access. (Expert Opinion)

Physical examination of arterial system

Character of peripheral pulses

Allen test

Bilateral upper extremity blood pressures

Physical examination of venous system

Evaluation for edema

Assessment of arm sizes comparability

Examination for collateral veins

Evaluation of veins:

Augmented palpation

Examination for evidence of prior central or peripheral venous catheterization

Examination for evidence of arm, chest, or neck surgery/trauma

Cardiovascular evaluation

Examination for evidence of heart failure

# Scelta dell'accesso vascolare per emodialisi

## 3.ecocolordoppler

### Statements: Vessel Mapping for Vascular Access

7.3 KDOQI suggests selective preoperative ultrasound in patients at high risk of AV access failure (Table 7.2) rather than routine vascular mapping in all patients (Conditional Recommendation, Low Quality of Evidence).

7.4 KDOQI considers it reasonable to use various imaging studies as needed to evaluate the suitability of vessels for AV access creation such as ultrasonography for peripheral vessels (including intraoperative ultrasound) and venography for suspected central vein occlusion, while considering the patient's clinical circumstances and residual kidney function. (Expert Opinion)

**Table 7.2.** Examples of Risk Factors For Which Vessel Mapping May Be Beneficial


Clinical Problem	Risk Factors
Fistula failure	Elderly age, female, comorbidities (eg, peripheral vascular disease, coronary artery disease), small pediatric patients
Peripheral vessel damage	Ipsilateral: PICC insertion, other iatrogenic (eg, venipuncture), self-inflicted (eg, IVDU), disease states (eg, vasculitis), radial artery harvesting for CABG
Central venous stenosis	Multiple CVCs; prolonged CVC duration; cardiac implantable electronic device; PICC; surgery or trauma to neck, chest, upper extremity
Limitations to physical examination	Morbid obesity, suboptimal conditions (eg, patient dehydrated or vasoconstricted), poor skin integrity, patient refusal

Variabilità legata all'operatore, che potrebbe essere diverso da chi allestisce l'accesso, costi, disagio del paziente, allungamento dei tempi,...



# Scelta dell'accesso vascolare per emodialisi

## 3. ecocolordoppler



**Table 2.** Site of AVF (in all patients who underwent surgery n = 206).

Site of AVF	Clinical (n = 105)	Ultrasound (n = 101)	p value*
Radiocephalic	37 (35.2%) <sup>a</sup>	29 (28.7%) <sup>a</sup>	< 0.001
Ulnobasilic	1 (1.0%) <sup>a</sup>	0 (0.0%) <sup>a</sup>	
Brachiocephalic	50 (47.6%) <sup>a</sup>	49 (48.5%) <sup>a</sup>	
Brachiobasilic	8 (7.6%) <sup>a</sup>	23 (22.8%) <sup>b</sup>	
(superficialization/transposition)			
Negative surgical exploration**	9 (8.6%) <sup>a</sup>	0 (0.0%) <sup>b</sup>	

AVF: arteriovenous fistulas.


Source: Own authorship (2019). \*Chi-square test. \*\* 1 Radiocephalic, 6 Brachiocephalics and 2 Brachiobasilics.

Different letters on the same line indicate difference in frequency between groups by analysis of residues at 5% significance.

studio randomizzato e controllato  
popolazione brasiliana in dialisi  
diametro vena  $\geq 2.5$  mm  
arteria  $\geq 2$  mm  
sopravvivenza primaria (non assistita)  
criterio clinico

# Scelta dell'accesso vascolare per emodialisi

## 3.ecocolordoppler



Log-rank test, p=0.042

Kaplan–Meier curve for primary unassisted patency. Kaplan–Meier curve for primary patency survival (days) in the ultrasound group – 97 patients (dotted line) and clinical group – 97 patients (straight line). p = 0.042 (log-rank analysis).

**Table 4.** Primary failure subtypes (n = 206).

Variable	All cases (%)	Clinical group (n = 105)		Ultrasound group (n = 101)		Logistic regression	
		Cases	Odds	Cases	Odds	OR (CI 95%)	p value*
Primary failure	37 (18.0)	28	0.39	9	0.10	0.27 (0.12–0.61)	0.002
Negative surgical exploration	9 (4.4)	9	0.09	0	–	–	–
Immediate failure	22 (10.7)	16	0.18	6	0.06	0.35 (0.13–0.93)	0.037
Early thrombosis	6 (2.9)	3	0.029	3	0.031	1.04 (0.20–5.28)	0.961

**Table 5.** Cost-effectiveness between groups (n = 206).


Groups	Average cost (US\$)	Effectiveness (primary patency) (days)	Incremental cost-effectiveness (US\$/day of the fistula)	Functional dialysis use time (days of dialysis/AVF)
Clinical	155.44	120.37	1.29	97.95
Doppler	196.47	153.63	1.28	125.75

AVF: arteriovenous fistulas.

\*Except grafts. Source: Own authorship (2019). Dollar quotation (US\$1.00 = R\$3.86).

Lopes JRA, Marques ALB, Correa JA. Randomised clinical study of the impact of routine preoperative Doppler ultrasound for the outcome of autologous arteriovenous fistulas for haemodialysis. J Vasc Access. 2021;22(1):107-114.


# Scelta dell'accesso vascolare per emodialisi



## 3.ecocolordoppler

### meta-analisi di studi randomizzati

Forest plot illustrating the pooled estimate of the immediate arteriovenous fistulae failure rate in patients with pre-operative routine Doppler ultrasound mapping (US) vs. patients evaluated with clinical examination or selective US. Odds ratio (OR) is shown with 95% confidence intervals (CI).



solo due sopravvivenza ad un anno

Forest plot illustrating the pooled estimate of the early/midterm adequacy for hemodialysis in patients with pre-operative routine Doppler ultrasound mapping (US) vs. patients evaluated with clinical examination or selective US. Odds ratio (OR) is shown with 95% confidence intervals (CI)

# Scelta dell'accesso vascolare per emodialisi

## 3. Ecocolordoppler

Posizione seduta di fronte all'operatore con arto superiore appoggiato su un tavolino o supina, solo canottiera o manica corta, ambiente non troppo freddo (anche il gel andrebbe scaldato), con possibilità di oscuramento



SHOT ON REDMI 7  
AI DUAL CAMERA

Ecocolordoppler richiede certa esperienza dell'esaminatore, adeguato ecografo, sonda (lineare) non invasivo, sicuro, e ripetibile  
unica tecnica diagnostica che valuta contemporaneamente anatomia dei vasi (B-mode) e flussi (colordoppler), può essere effettuato dallo stesso operatore che eseguirà l'intervento



# Scelta dell'accesso vascolare per emodialisi

## 3. Ecocolordoppler

### Statements: Optimal Vessel Size of Artery and Vein for AV Access Creation

- 7.5 KDOQI considers it reasonable that while there is no minimum diameter threshold to create an AVF, arteries and veins of  $< 2$  mm in diameter should undergo careful evaluation for feasibility and quality to create a functioning AVF. (Expert Opinion)
- 7.6 KDOQI considers it reasonable to evaluate multiple characteristics of vessel quality for AVF creation (size, distensibility, flow, etc). (Expert Opinion)

**distretto venoso  
(da distale a prossimale)**


**pervietà vasale (lume anecogeno, comprimibile, flusso)  
diametro ( $> 2$  mm?)  
distensibilità vasale (laccio per 2' ?)  
aspetto della parete (sottile e regolare)  
decorso del vaso (rettilineo, profondità  $< 6$  mm)  
presenza di circoli collaterali**



# Scelta dell'accesso vascolare per emodialisi

## 3. Ecocolordoppler

vena



Pervietà del vaso





# Scelta dell'accesso vascolare per emodialisi

## 3. Ecocolordoppler

Decorso del vaso

vena

Diametro del vaso




# Scelta dell'accesso vascolare per emodialisi

Distensibilità del vaso

3.Ecocolordoppler

vena



**Figure 1.** Transverse gray scale sonograms of the cephalic vein (cursors) at the wrist before placement of a forearm tourniquet (**A**) and after placement of the tourniquet (**B**) show dilatation of the vein from a subthreshold diameter of 0.17 cm (**A**) to a diameter of 0.27 cm (**B**), which met the threshold for recommendation of a forearm fistula. The subsequently placed fistula was successful in this patient.

# Scelta dell'accesso vascolare per emodialisi

## 3. Ecocolordoppler

### Doppler

### vena




FIG. 2. Normal Doppler waveform of a vein.




FIG. 3. Increasing of venous flow during deep inspiration and decreasing during expiration.

# Scelta dell'accesso vascolare per emodialisi

## 3. Ecocolordoppler

### Statements: Optimal Vessel Size of Artery and Vein for AV Access Creation

- 7.5 KDOQI considers it reasonable that while there is no minimum diameter threshold to create an AVF, arteries and veins of <2 mm in diameter should undergo careful evaluation for feasibility and quality to create a functioning AVF. (Expert Opinion)
- 7.6 KDOQI considers it reasonable to evaluate multiple characteristics of vessel quality for AVF creation (size, distensibility, flow, etc). (Expert Opinion)

**distretto arterioso**

**da prossimale a distale:**

**succlavia, ascellare, brachiale, radiale ed ulnare**

**diametro > 2 mm?**

**spessore miointimale**

**alterazioni della parete**

**anomalie di decorso (biforcazione alta)**

**lesioni steno-ostruttive**

**flussi ematico**

**capacità di dilatazione**

minor attenzione data all'arteria



# Scelta dell'accesso vascolare per emodialisi

## 3. Ecocolordoppler

arteria



Diametro del vaso

# Scelta dell'accesso vascolare per emodialisi

## 3. Ecocolordoppler

arteria






Flusso



# Scelta dell'accesso vascolare per emodialisi

## 3. Ecocolordoppler

arteria



Flusso

15:Fistole 11 Probe:5412 AIP SCI

15:Fistole 11 Probe:5412 AIP SCI S.V.: 0.51 Depth: 1.4

15:Fistole 11 Probe:5412 AIP SCI S.V.: 0.5mm Depth: 1.3cm

# Scelta dell'accesso vascolare per emodialisi

## 3. Ecocolordoppler

arteria




## Aspetto della parete



calcificazioni aree di iperecogenicità nella parete del vaso, rendendo irregolare l'aspetto della parete


# Scelta dell'accesso vascolare per emodialisi




arteria

## 3. Ecocolordoppler

### Spessore miointimale



lo spessore mio-intimale è misurato analizzando l'arteria in senso longitudinale



failure group (14)	patent group (24)
$0.46 \pm 0.08$ mm	$0.40 \pm 0.09$ mm


$p = 0.032$

Ku YM, Kim YO, Kim JI, Choi YJ, Yoon SA, Kim YS, Song SW, Yang CW, Kim YS, Chang YS, Bang BK. Ultrasonographic measurement of intima-media thickness of radial artery in pre-dialysis uraemic patients: comparison with histological examination. Nephrol Dial Transplant. 2006 Mar;21(3):715-20

# Scelta dell'accesso vascolare per emodialisi

## 3. Ecocolordoppler

### Test dell'iperemia reattiva



**arteria**

buona compliance vascolare



# Scelta dell'accesso vascolare per emodialisi

## Indice di resistenza




FIG. 6. Doppler “high-resistance” waveform at clenched fist (A) and Doppler “low resistance” waveform after releasing the fist (B) (reactive hyperemia).

## 3. Ecocolordoppler

### arteria





FIG. 7. Calculation of the resistance index (A = maximal systolic velocity; B = minimal diastolic velocity).

### 3. Ecocolordoppler

### diametri



**Figure 1.** Secondary patency of radiocephalic AVFs in relation to cephalic vein diameter. Results were significantly inferior in the presence of a cephalic vein diameter  $< 4.3$  mm (lower three quartiles) compared with larger veins. Kaplan-Meier curves are truncated at 24 months. The number of patients at risk, patency probability, and 95% CI at each follow-up interval are shown at the bottom of the figure.

127 pz valutati prospettivamente ed analizzati retrospettivamente  
 135 FAV: 57 radio (arteriotomia 10-15 mm)  
 78 brachiocefaliche (arteriotomia 7-8 mm)  
 6-8 settimane, clinico -> eco

**Criteri:**

arteria radiale  $\geq 2$  mm  
 vena cefalica  $\geq 3$  mm

diametro minimo della vena dopo 1' con laccio

No predictors of primary patency  
 Age for primary assisted patency

+ sesso

80.4% successo

Kakkos SK, Kaplanis N, Papachristou EC, Papadoulas SI, Lampropoulos GC, Tsolakis IA, Goumenos DS. The Significance of Inflow Artery and Tourniquet Derived Cephalic Vein Diameters on Predicting Successful Use and Patency of Arteriovenous Fistulas for Haemodialysis. Eur J Vasc Endovasc Surg. 2017 Jun;53(6):870-878



### 3. Ecocolordoppler

diametri

76% successo

**Table 3.** Predictors of brachiocephalic AVF patency on univariate and multivariate analysis.

Patency predictors	Results Patency results <sup>a</sup>	Univariate analysis <sup>b</sup>	Multivariate analysis <sup>b</sup>
<b>Primary patency</b>			
BA $\varnothing \leq 4.1$ mm (LQ)	21.9% vs. 49.4% @ 3 years, $p = .002$	HR 2.69, 95% CI 1.39–5.2, $p = .003$	HR 2.65, 95% CI 1.37–5.15, $p = .004$
CV $\varnothing \leq 3.8$ mm (LQ)	27.6% vs. 46.6% @ 3 years, $p = .066$	HR 1.81, 95% CI 0.94–3.50, $p = .078$	NS
Dyslipidaemia	11.3% vs. 45.2% @ 5 years, $p = .029$	HR 2.00, 95% CI 1.04–3.85, $p = .037$	HR 1.97, 95% CI 1.02–3.80, $p = .043$
<b>Primary assisted patency</b>			
BA $\varnothing \leq 4.1$ mm (LQ)	21.9% vs. 55.9% @ 3 years, $p = .001$	HR 3.38, 95% CI 1.65–6.90, $p = .001$	HR 3.1, 95% CI 1.5–6.4, $p = .002$
CV $\varnothing \leq 3.8$ mm (LQ)	29.6% vs. 51.9% @ 4 years, $p = .021$	HR 1.97, 95% CI 0.97–4.00, $p = .061$	NS
Dyslipidaemia	21.2% vs. 64.9% @ 4 years, $p = .015$	HR 2.36, 95% CI 1.15–4.87, $p = .020$	HR 2.23, 95% CI 1.08–4.61, $p = .002$
Hypertension	36.1% vs. 82.1% @ 5 years, $p = .053$	HR 3.68, 95% CI 0.88–15.44, $p = .075$	NS
Antithrombotic agents	31.0% vs. 56.7% @ 4 years, $p = .069$	HR 1.93, 95% CI 0.93–3.99, $p = .078$	NS
Dual antithrombotic agents	27.8% vs. 77.4% @ 6 months, $p = .031$	HR 3.52, 95% CI 1.01–12.24, $p = .048$	NS
<b>Secondary patency</b>			
BA $\varnothing \leq 4.1$ mm (LQ)	27.8% vs. 54.0% @ 3 years, $p = .011$	HR 2.62, 95% CI 1.20–5.72, $p = .015$	HR 2.6, 95% CI 1.17–5.6, $p = .019$
Dual antithrombotic agents	27.8% vs. 85.2% @ 6 months, $p = .007$	HR 4.99, 95% CI 1.36–4.99, $p = .015$	HR 4.64, 95% CI 1.27–16.94, $p = .020$
<b>Functional secondary patency</b>			
BA $\varnothing \leq 4.1$ mm (LQ)	26.9% vs. 47.5% @ 4 years, $p = .007$	HR 2.44, 95% CI 1.23–4.81, $p = .010$	HR 3.43, 95% CI 1.66–7.07, $p = .001$
Peripheral arterial disease	33.3% vs. 57.0% @ 2 years, $p = .021$	HR 2.73, 95% CI 1.11–6.75, $p = .029$	HR 3.47, 95% CI 1.35–8.88, $p = .010$
Dual antithrombotic agents	22.2% vs. 57.8% @ 6 months, $p = .009$	HR 3.80, 95% CI 1.27–11.36, $p = .017$	HR 3.41, 95% CI 1.14–10.19, $p = .028$

### 3. Ecocolordoppler

## 2. riferimenti forniti dalla letteratura

diametri

**Methods:** A prospective, observational study was performed on 122 patients (66 men) who underwent primary RCAVF creation. Internal diameters of cephalic vein (CVd) and radial artery (ARd), venous distensibility (VD), resistance index (RI) and endothelial function by flow mediated dilatation (FMD) were determined by ultrasound examination before AVF placement. AVF maturation was observed by measuring blood flow (Qa) and CVd 0, 14 and 28 days after creation. Depending on the time when AVFs attained maturity (Qa  $\geq$  500 mL/min, CVd  $\geq$  5 mm), patients were divided into three groups: (i) successful maturation (after four weeks), (ii) prolonged maturation (within eight weeks) and (iii) failure to mature.


**Results:** Only 11% of patients failed to achieve a mature RCAVF. Successful AVF maturation occurred in 53% of patients and prolonged maturation in 36% of patients. ROC analysis defined the limits of variables relevant for RCAVF success (CVd > 1.8 mm, ARd > 1.6 mm, VD > 0.4 mm). Female sex was associated with prolonged maturation (OR 0.35, 95% CI=0.17-0.72; P=0.005) having a significantly smaller ARd (1.83 vs. 2.01 mm, P=0.01) but better FMD (2981.5 vs. 2689.5, P=0.02) compared to men.

**Conclusions:** ARd  $\leq$  1.6 mm, CVd  $\leq$  1.8 mm and VD  $\leq$  0.4 mm are exact cut-off points, which best predict nonmaturation of RCAVF. Women need extended time for adequately matured AVF.

### 3. Ecocolordoppler

### diametri

studio retrospettivo 80 pz  
primo allestimento  
FAV radiocefaliche  
arteriotomia 10 mm  
6 settimane  
criterio clinico -> eco



cut-off 2.3 mm

**Table 2** Pre- and intraoperative vessel parameters


Variable	Total patients (n = 80)	Group functioning AVF (n = 62)	Group nonfunctioning AVF (n = 18)	$\chi^2$	p value
Preoperative diameter radial artery, mm, mean $\pm$ SEM	2.4 $\pm$ 0.1	2.5 $\pm$ 0.1	2.19 $\pm$ 0.1	5.23	0.01
Preoperative diameter cephalic vein, mm, mean $\pm$ SEM	3.1 $\pm$ 0.1	3.2 $\pm$ 0.1	2.8 $\pm$ 0.8	3.7	0.07
Intraoperative AVF flow, mL/min, mean $\pm$ SEM	180 $\pm$ 15	201 $\pm$ 18	111 $\pm$ 17	7.09	0.01
Intraoperative AVF PI, mean $\pm$ SEM	0.9 $\pm$ 0.1	0.77 $\pm$ 0.1	1.21 $\pm$ 0.2	6.5	0.04
Postoperative AVF flow, mL/min, mean $\pm$ SEM	327 $\pm$ 26	401 $\pm$ 27	87 $\pm$ 24	16.29	0.01

Abbreviations: AVF, arteriovenous fistula; PI, pulsating index; SEM, standard error of mean.

### 3. Ecocolordoppler

## 2. riferimenti forniti dalla letteratura


diametri



Diagonal segments are produced by ties.

Cephalic vein cutoff diameter: **1.55mm**

Area	SE	p value	95% CI	
.795	.027	.000	.741	.848



Diagonal segments are produced by ties.

Radial Artery Cut off diameter: **1.65 mm**

Area	SE	P value	95% CI	
.811	.026	.000	.760	.863

Studio prospettico di coorte 324 pz  
FAV radiocefaliche (primo)  
1/4/6 settimane  
criterio dei 6

66% maturazione FAV



# diametri

**Table 2.** Chi-square analysis of between two groups (primary functional maturation versus non-maturation).

	No maturation		Maturation		<i>p</i>
	<i>n</i>	%	<i>n</i>	%	
<b>Gender</b>					
Female	39	48.8	41	51.2	.001
Male	71	29.1	173	70.9	
<b>Age at surgery</b>					
18–65 years	54	37.8	89	62.2	.401
66–75 years	25	32.9	51	67.1	
> 75 years	27	29.3	65	70.7	
<b>Diabetes mellitus</b>					
No diabetes mellitus	61	33.0	124	67.0	.648
Diabetes mellitus	36	35.6	65	64.4	
<b>Hypertension</b>					
No Hypertension	13	33.3	26	66.7	.885
Hypertension	67	34.5	127	65.5	
<b>IHD</b>					
No IHD	68	32.9	139	67.1	.605
IHD	18	36.7	31	63.3	
<b>CHF</b>					
No CHF	85	34.7	160	65.3	.079
CHF	1	9.1	10	90.9	
<b>Local or general anaesthetic</b>					
Local anaesthetic	100	35.1	202	66.9	.455
General anaesthetic	9	40.9	13	59.1	
<b>Cephalic vein diameter (mm)</b>					
Up to 1.55	86	61.9	53	38.1	< .001
> 1.55	25	13.6	159	86.4	
<b>Radial artery diameter (mm)</b>					
Up to 1.65	92	65.7	48	34.3	< .001
> 1.65	15	8.5	162	91.5	

Note. total *n* = 324. CHF = congestive heart failure; IHD = ischaemic heart disease.

**Table 5.** The univariate and multivariate binary logistic regression results for independence of variables (*n* = 324).

	Univariate Odds ratio	95% CI	<i>p</i>	Multivariate Odds ratio	95% CI	<i>p</i>
<b>Gender</b>						
Female	Ref			Ref		
Male	2.32	1.38–3.89	.001	1.66	.82–3.38	.161
<b>Age (years)</b>						
18–65	Ref					
> 65	1.35	0.85–2.17	.207			
<b>General/local anaesthetic</b>						
Local	Ref					
General	0.72	0.30–1.73	.457			
<b>Diabetes mellitus</b>						
No diabetes	Ref					
Diabetes	0.89	0.53–1.48	0.648			
<b>IHD</b>						
No IHD	Ref					
IHD	0.84	0.44–1.61	.605			
<b>CHF</b>						
No CHF	Ref					
CHF	5.31	0.67–42.20	.114			
<b>Hypertension</b>						
No hypertension	Ref					
Hypertension	0.95	0.46–1.96	.885			
<b>Vein diameter (mm)</b>						
Up to 1.55	Ref			Ref		
> 1.55	10.30	6.00–17.76	< .001	4.57	2.42–8.63	< .001
<b>Artery diameter (mm)</b>						
Up to 1.65	Ref			Ref		
> 1.65	20.70	10.98–39.01	< .001	12.26	6.27–23.97	< .001

CHF = congestive heart failure; IHD = ischaemic heart disease.

### 3. Ecocolordoppler

diametri

**Table 7.** Stepwise regression analysis demonstrating cutoff points (cephalic vein and radial artery diameter) and ranges with their subsequent maturation success and test of probability.

		Univariate <i>p</i>	Multivariate Odds ratio	95% CI	Maturation (%)	<i>p</i>
Cephalic vein diameter (mm)	< 1.55	< .001	Ref		38.1	
	1.56–1.99		4.29	1.80–10.23	81.5	.001
	2.00+		4.57	2.15–9.73	88.5	< .001
Radial artery diameter (mm)	< 1.65	< .001	Ref		34.3	
	1.66–1.99		7.91	3.17–19.76	86.3	< .001
	2.00+		15.95	6.89–36.95	93.7	< .001



### 3. Ecocolordoppler

Diametro della vena con o senza laccio?  
possibile aumento del diametro > 30%

vena  
diametro


Dove misurare il diametro della vena?  
diametro minimo del tratto di efflusso della FAV  
diametro del tratto perianastomotico  
diametro medio del tratto di efflusso  
...non specificato come o quale diametro misurato

Indicare un cutoff per il diametro probabilmente non è corretto, pensando che all'aumentare del diametro maggior è la probabilità di fistola funzionante

Zamboli P, Fiorini F, D'Amelio A, Fatuzzo P, Granata A. Color Doppler ultrasound and arteriovenous fistulas for hemodialysis. J Ultrasound. 2014 Jul 11;17(4):253-63


Kosa SD, Al-Jaishi AA, Moist L, Lok CE. Preoperative vascular access evaluation for haemodialysis patients. Cochrane Database Syst Rev. 2015 Sep 30;2015(9)

Cornacchiari M, Mudoni A, Borin F, Stasi A, Ponticelli MG, Visciano B, Guastoni C. [Evaluation via ecocolordoppler before creating a vascular access for hemodialysis: a monocentric experience]. G Ital Nefrol. 2020 Jun 10;37(3)



moda 2 mm  
 media 2.3 mm } vena

analisi retrospettiva di dati raccolti  
 prospetticamente  
 148 pz radiocefaliche clinico a 1 aa  
 diametro arteria e vena con laccio al polso



**Fig. 4.** Primary patency by tertiles of radial artery diameter: Kaplan Meier curves. Curve A:  $\leq 2.0$  mm, B:  $\geq 2.1$  mm and  $\leq 2.5$  mm, C:  $\geq 2.6$  mm (overall  $P = 0.042$ ). Numbers at risk are given below.

primary failure (criterio clinico 6 settimane) 11%

# vena distensibilità

**Table 1.** Fistula Outcomes Sorted by Pretourniquet Cephalic Vein Diameter and Sex

Vein Diameter, cm	Fistulas, n	Adequate, n (%)	Inadequate, n (%)
Female	31	6/31 (19)*	25/31 (81)
Pretourniquet <0.25	23	4/23 (17)†	19/23 (83)
Pretourniquet ≥0.25	8	2/8 (25)†	6/8 (75)
Male	42	20/42 (48)*	22/42 (52)
Pretourniquet <0.25	22	11/22 (50)†	11/22 (50)
Pretourniquet ≥0.25	20	9/20 (45)†	11/20 (55)

**Table 3.** Preoperative Sonographic Measurements by Fistula Outcome

Preoperative Parameter	Inadequate Fistulas (n = 47)	Adequate Fistulas (n = 26)	P
Artery diameter, cm	0.26 ± 0.01	0.30 ± 0.01	.001
Vein diameter, cm			
Before tourniquet	0.22 ± 0.01	0.23 ± 0.01	.962
After tourniquet	0.30 ± 0.01	0.33 ± 0.01	.006
PSV, cm/s	0.55 ± 0.03	0.60 ± 0.04	.360
EDV, cm/s	0.019 ± 0.004	0.011 ± 0.006	.296

Values are mean ± SEM. EDV indicates end-diastolic velocity; and PSV, peak systolic velocity.

analisi retrospettiva di dati raccolti  
prospettivamente  
FAV radiocefaliche  
In 97 pz dei quali 73 disponibile follow up  
Criteri:  
arteria radiale ≥ 2 mm  
vena cefalica al polso ≥ 2.5 mm  
6 mesi clinico

64% failure

Lockhart ME, Robbin ML, Fineberg NS, Wells CG, Allon M. Cephalic vein measurement before forearm fistula creation: does use of a tourniquet to meet the venous diameter threshold increase the number of usable fistulas? J Ultrasound Med. 2006 Dec;25(12):1541-5

### 3. Ecocolordoppler

flusso ematico




Fig 1. Receiver operating characteristic (ROC) curve of minimum vein diameter (MVD) of <2.7 mm as a predictor of native arteriovenous fistula (AVF) failure to mature (FTM; area under the curve [AUC], 0.72; 95% confidence interval [CI], 0.60-0.85;  $P = .002$ ).




Fig 2. Receiver operating characteristic (ROC) curve of radial artery volume flow (VE) of <50 mL/min as a predictor of native arteriovenous fistula (AVF) failure to mature (FTM; area under the curve [AUC], 0.64; 95% confidence interval [CI], 0.50-0.78;  $P = .054$ ).


studio retrospettivo  
152 pz -> 149 -> 47 (32%)  
failure to mature

diametro vena senza laccio  
3 misure a distanza di 5 cm  
criterio clinico

# 3. Ecocolordoppler

Vessel characteristics	Mean; standard deviation (range)	P (95% CI)
<b>Artery</b>		
Diameter, mm		
Radial artery (n = 67)	3.7; 1.2 (1.9-5.9)	.6 (-0.6 to -0.3)
Brachial artery (n = 76)	3.6; 1.3 (1.5-6.7)	
Peak systolic velocity, cm/s		
Radial artery (n = 62)	75; 20 (35.7-147.8)	<.001 (-20.4 to -6.0)
Brachial artery (n = 72)	89; 22 (47.2-159.9)	
VF, mL/min		
Radial artery (n = 66)	64; 39 (7-175)	<.001 (-180.9 to -131.7)
Brachial artery (n = 79)	220; 94 (62-501)	
<b>Vein</b>		
Average vein diameter, mm		
Lower cephalic	3.0; 0.8 (1.5-4.7)	
Upper cephalic	3.6; 1.1 (1.1-6.1)	
Basilic vein	4.9; 1.3 (3.2-7.3)	
MVD, mm		
Lower cephalic	2.7; 0.7 (1.2-4.3)	
Upper cephalic	3.3; 1.1 (0.9-5.9)	
Basilic vein	4.6; 1.1 (3.2-6.7)	

CI, Confidence interval; MVD, minimum vein diameter; VF, volume flow.



**Fig 3.** Receiver operating characteristic (ROC) curve of model 1: gender, radial artery VF <50 mL/min, and MVD <2.7 mm; model 2: gender and history of peripheral vascular disease and diabetes; and model 3: MVD <2.7 mm and a radial artery VF <50 mL/min. Model 1: area under the curve (AUC), 0.81; 95% confidence interval (CI), 0.70-0.91;  $P < .01$ . Model 2: AUC, 0.68; 95% CI, 0.55-0.81;  $P = .011$ . Model 3: AUC, 0.77; 95% CI, 0.66-0.88;  $P < .01$ .

flusso ematico → radiocefaliche → età non significativa

Masengu A, McDaid J, Maxwell AP, Hanco JB. Preoperative radial artery volume flow is predictive of arteriovenous fistula outcomes. J Vasc Surg. 2016 Feb;63(2):429-35



# Scelta dell'accesso vascolare per emodialisi

## 4. Flebografia

### Statements: Vessel Mapping for Vascular Access

- 7.3 KDOQI suggests selective preoperative ultrasound in patients at high risk of AV access failure (Table 7.2) rather than routine vascular mapping in all patients (Conditional Recommendation, Low Quality of Evidence).
- 7.4 KDOQI considers it reasonable to use various imaging studies as needed to evaluate the suitability of vessels for AV access creation such as ultrasonography for peripheral vessels (including intraoperative ultrasound) and venography for suspected central vein occlusion, while considering the patient's clinical circumstances and residual kidney function. (Expert Opinion)





# Scelta dell'accesso vascolare per emodialisi

## 4. Flebografia

Consecutive patients with chronic kidney disease (n = 137) after an initial estimation of the AV access type, based on physical examination, had USVM and UEV to detect vascular pathology that could potentially alter the original plan. USVM changed the preoperative plan in 31 (22.6%) patients; this was 36.7% (n = 18) in diabetics compared with 14.8% (n = 13) in nondiabetics (p < .001). Patients for whom USVM changed the type of planned AV access had been on hemodialysis significantly longer (2.7 years vs 0.9 years; p < .001). Venography identified 18 patients with central vein stenosis that led to a site change in 12 of them. Significant venous stenosis in patients with a history of two or more central catheters placed and patients without such a history was 93% and 1%, respectively. In eight patients, intraoperative findings dictated AV graft placement or creation of a central AVF. The original plan was revised in 31%, and this rate was similar for distal AVF, central AVF, and AV grafts (38%, 26%, and 43%, respectively; all p > .05). The 30-day patency rate was 92.2%. A significant proportion of patients have vascular pathology severe enough to alter the access type as suggested by physical examination alone. USVM should be routinely performed, whereas UEV should be selectively performed in patients with a history of surgery or instrumentation of their central veins.

### 4. Flebografia

> J Vasc Access. 2006 Jul-Sep;7(3):123-8. doi: 10.1177/112972980600700306.

#### Impact of pre-operative venography on the planning and outcome of vascular access for hemodialysis patients

M A Elsharawy<sup>1</sup>, K M Moghazy

**Patients and methods:** A prospective study was performed on all patients with end-stage renal disease (ESRD) who had HD access procedures and pre-operative venography between October 2003 and November 2005. Upper limb venography was done for all patients except those that required primary access and had visible veins. All patients had HD immediately after the venography. Access procedure selection was based on the result of the venography. The complications of venography, the surgical procedure and the outcome were recorded.



**Results:** One hundred and twenty-nine patients with ESRD who had pre-operative venography were included in this study. They were mostly middle age (mean age +/- SD = 41 +/- 15.5 yrs) with a high rate of diabetes mellitus (53%). No single complication was reported. A graft was placed in six patients (5%) only. Unsuccessful surgical exploration was 0%. Early failure was in 10 patients (8%).

**Conclusion:** Pre-operative venography resulted in an increase in the number of AVFs. It can improve the results of HD access procedures by selecting the most suitable veins.



# Scelta dell'accesso vascolare per emodialisi

## Quale anastomosi?

Model (artery + vein)	Size, mm	STS	Short STS	Open STS	45° ETS	90° ETS
3 + 3	3.0 × 1.5	X				
3 + 3	4.5 × 1.5	X	X	X	X	X
3 + 3	6.0 × 1.5	X				
4 + 6	3.0 × 1.5	X				
4 + 6	4.5 × 1.5	X	X	X	X	X
4 + 6	6.0 × 1.5	X				
4 + 6	6.0 × 4.0	X			X	X








# Scelta dell'accesso vascolare per emodialisi

## Validation of a patient-specific hemodynamic computational model for surgical planning of vascular access in hemodialysis patients

Anna Caroli<sup>1,10</sup>, Simone Manini<sup>1,10</sup>, Luca Antiga<sup>2</sup>, Katia Passera<sup>1</sup>, Bogdan Ene-lordache<sup>1</sup>, Stefano Rota<sup>3</sup>, Giuseppe Remuzzi<sup>3</sup>, Aron Bode<sup>4</sup>, Jaap Leermakers<sup>4</sup>, Frans N. van de Vosse<sup>5,6</sup>, Raymond Vanholder<sup>7</sup>, Marko Malovrh<sup>8</sup>, Jan Tordoir<sup>4</sup> and Andrea Remuzzi<sup>1,9</sup> on behalf of the ARCH project Consortium<sup>11</sup>





# Scelta dell'accesso vascolare per emodialisi

## FAV nativa

PRO

CONTRO



Murad MH, Elamin MB, Sidawy AN, Malaga G, Rizvi AZ, Flynn DN, Casey ET, McCausland FR, McGrath MM, Vo DH, El-Zoghby Z, Duncan AA, Tracz MJ, Erwin PJ, Montori VM. Autogenous versus prosthetic vascular access for hemodialysis: a systematic review and meta-analysis. J Vasc Surg. 2008 Nov;48(5 Suppl):34S-47S

# Scelta dell'accesso vascolare per emodialisi

## ecocolordoppler

PRO

CONTRO

↓  
poco costosa

↓  
non invasiva (no radiazioni ionizzanti, non mezzo di contrasto iodato)

↑  
facilmente disponibile

valutazione morfologica e dinamica dell'accesso

presenza di valvole

operatore dipendente

↓  
campo visivo (acquisire molte immagini)

immagine bi-dimensionale

non da immagini del sistema venoso centrale (sterno, clavicola, coste)

# Scelta dell'accesso vascolare per emodialisi

## flebografia

PRO

CONTRO

gold standar per la valutazione del sistema venoso

permette di identificare stenosi dei vasi centrali



più costosa



più invasiva (radiazioni ionizzanti, mezzo di contrasto iodato\_ tossicità, allergia\_)

non disponibile in tutti gli ospedali

richiede più tempo per preparare il paziente

necessaria sala adeguata (asettica, schermata)

## Scelta dell'accesso vascolare?



Proporre al paziente giusto  
l'accesso vascolare giusto  
al momento giusto



GRAZIE!!!